Dihydroergotamine Mesylate Patent Expiration
Dihydroergotamine Mesylate is used for acute treatment of migraine with or without aura. It was first introduced by Bausch Health Us Llc
Dihydroergotamine Mesylate Patents
Given below is the list of patents protecting Dihydroergotamine Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Trudhesa | US11185497 | Intranasal delivery of dihydroergotamine by precision olfactory device | Jan 04, 2039 | Impel Pharms |
| Trudhesa | US11266799 | In-line nasal delivery device | Nov 05, 2036 | Impel Pharms |
| Trudhesa | US9919117 | Nozzles for nasal drug delivery | Mar 17, 2033 | Impel Pharms |
| Trudhesa | US10940278 | Nozzles for nasal drug delivery | Jan 23, 2033 | Impel Pharms |
| Trudhesa | US10507295 | Nasal drug delivery device | Dec 25, 2032 | Impel Pharms |
| Trudhesa | US9550036 | Nasal drug delivery device | Sep 05, 2032 | Impel Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dihydroergotamine Mesylate's patents.
Latest Legal Activities on Dihydroergotamine Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Dihydroergotamine Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 11 Jul, 2024 | US9550036 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Jul, 2024 | US10940278 |
| Change in Power of Attorney (May Include Associate POA) Critical | 02 Apr, 2024 | US11185497 |
| Email Notification Critical | 02 Apr, 2024 | US11185497 |
| Change in Power of Attorney (May Include Associate POA) Critical | 01 Apr, 2024 | US9550036 |
| Email Notification Critical | 01 Apr, 2024 | US9550036 |
| Email Notification Critical | 29 Mar, 2024 | US10940278 |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 Mar, 2024 | US10940278 |
| Email Notification Critical | 28 Mar, 2024 | US11266799 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Mar, 2024 | US11266799 |
Dihydroergotamine Mesylate's Family Patents
Explore Our Curated Drug Screens
Dihydroergotamine Mesylate Generic API Manufacturers
Several generic applications have been filed for Dihydroergotamine Mesylate. The first generic version for Dihydroergotamine Mesylate was by Padagis Us Llc and was approved on Apr 28, 2003. And the latest generic version is by Cipla Ltd and was approved on Sep 20, 2024.
Given below is the list of companies who have filed for Dihydroergotamine Mesylate generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL
Amneal Pharmaceuticals Llc has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG/SPRAY | spray, metered | Discontinued | NASAL | N/A | Jan 4, 2022 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
2. CIPLA
Cipla Ltd has filed for 2 different strengths of generic version for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG/SPRAY | spray, metered | Prescription | NASAL | AB | May 20, 2020 |
| 1MG/ML | injectable | Prescription | INJECTION | AP | Sep 20, 2024 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
3. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | injectable | Prescription | INJECTION | AP | Aug 18, 2023 |
4. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | injectable | Prescription | INJECTION | AP | Jun 9, 2003 |
| 0.5MG/SPRAY | spray, metered | Prescription | NASAL | AB | Feb 28, 2020 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
5. HIKMA PHARMS
Hikma Pharmaceuticals has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Hikma Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Sep 15, 2017 |
6. PADAGIS US
Padagis Us Llc has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Padagis Us.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | injectable | Prescription | INJECTION | AP | Apr 28, 2003 |
Manufacturing Plant Locations New
Padagis Us's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Padagis Us as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
7. PROVEPHARM SAS
Provepharm Sas has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Provepharm Sas.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | injectable | Prescription | INJECTION | AP | Jan 7, 2020 |
Manufacturing Plant Locations New
Provepharm Sas's manufacturing plants are situated in 1 country - France. Given below are the details of these plant locations as well as the firm names of Provepharm Sas as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| France |
| |||
8. RUBICON
Rubicon Research Private Ltd has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Rubicon.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG/SPRAY | spray, metered | Prescription | NASAL | AB | Jun 22, 2023 |
Manufacturing Plant Locations New
Rubicon's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Rubicon as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| Canada |
| |||||
| India |
| |||||
9. SAGENT PHARMS INC
Sagent Pharmaceuticals Inc has filed for 1 generic for Dihydroergotamine Mesylate. Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/ML | injectable | Prescription | INJECTION | AP | Jul 11, 2018 |